Related Experiment Video
Updated: Jan 6, 2026
09:43
Databases to Efficiently Manage Medium Sized, Low Velocity, Multidimensional Data in Tissue Engineering
Published on: November 22, 2019
6.7K
Growth hormone therapy in progeria
Ab Sadeghi-Nejad1, Laurie Demmer
1Division of Pediatric Endocrinology, Tufts University School of Medicine, Floating Hospital for Children, Tufts-New England Medical Center, Boston, MA 02111, USA. asadeghi@tufts-nemc.org
Journal of Pediatric Endocrinology & Metabolism : JPEM
|July 24, 2007
Summary
Hutchinson-Gilford progeria involves aging-like catabolism. Growth hormone (GH) treatment showed potential to counteract these catabolic effects in a young child with progeria.
Area of Science:
- Gerontology
- Pediatric Endocrinology
- Molecular Biology
Background:
- Hutchinson-Gilford progeria (HGP) is a rare genetic disorder characterized by premature aging.
- Catabolic processes in HGP mirror those in normal aging, leading to early mortality.
- Growth hormone (GH) possesses anabolic properties that can counteract catabolism.
Observation:
- A young child diagnosed with Hutchinson-Gilford progeria was treated with growth hormone.
- The study monitored the effects of GH administration on the child's catabolic state.
Findings:
- Growth hormone administration ameliorated some catabolic effects associated with HGP.
- The anabolic properties of GH demonstrated a potential therapeutic benefit in this case.
Implications:
- GH therapy may offer a strategy to mitigate the aging-like catabolism in HGP.
- Further research is warranted to explore GH's role in managing HGP and related aging disorders.
